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Basic Mechanisms ofAsthma
Homer A. Boushey and John V. Fahy
Cardiovascular Research Institute, University of California San Francisco, San Francisco, California
Results of studies of the epidemiology, physiology, histopathology, and cell biology of asthma have revised our conception of the disease.
Epidemiologic studies have shown asthma to be an important cause of death, suffering, and economic hardship. Physiologic studies have shown
that asthma is a chronic illness characterized by persistent bronchial hyperreactivity. Histopathologic studies have shown characteristic changes:
epithelial damage, deposition of collagen beneath the basement membrane, eosinophilic and lymphocytic infiltration, and hypertrophy and hyperplasia
of goblet cells, submucosal glands, and airway smooth muscle. Studies of the functions of cells in the airway mucosa suggest that asthma may be
fundamentally mediated by a difference in the type of lymphocyte predominating in the airway mucosa but may also involve complex interactions
among resident and migratory cells. Asthma may thus result from sensitization of a subpopulation of CD4+ lymphocytes, the Th2 subtype, in the
airways. These lymphocytes produce a family of cytokines that favor IgE production and the growth and activation of mast cells and eosinophils,
arming the airways with the mechanisms of response to subsequent reexposure to the allergen. This conceptual model has stimulated research
along lines that will almost certainly lead to powerful new treatments, and it has already put current therapies in a new light, clarifying the role of
antiinflammatory agents, especially of inhaled corticosteroids. This conceptual model has some limitations: it ignores new evidence on the role of
the mast cell in producing cytokines and depends on results of studies of the effects of inhalation of allergen, although most asthma exacerbations
are provoked by viral respiratory infection. Preliminary studies suggest that viral infection and allergen inhalation may involve the activation of different
pathways, with viral infection activating production of cytokines by airway epithelial cells. Similar study of the mechanisms activated by inhalation of
air toxics may provide important clues as to how they might induce or exacerbate asthma. - Environ Health Perspect 103(Suppl 6):229-233 (1995)
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Introduction
The conception of the pathogenesis ofdis-
ease drives far more than the thoughts on
what treatments might be most effective. It
affects also the resources allocated to
research and care, the direction of the
research undertaken, and even the sympa-
thy extended and the public policies
adopted to protect those afflicted. For
asthma, the past 10 or 15 years have
brought about a dramatic change in the
conception ofpathogenesis that has in turn
led to the proposal ofpreviously unconsid-
ered mechanisms by which other inhaled
materials might worsen the condition.
Medicine's conception ofthe pathogen-
esis ofasthma has evolved over two millen-
nia, for the disease was known to
Hippocrates. The word asthma is derived
from the ancient Greek for panting, and
even the ancient world recognized that
asthma could cause death by suffocation
(1). In the 11th century, Moses
Maimonides recorded that death from
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asthma could occur "should the rules of
management go unheeded and one's
desires and habits be followed indiscrimi-
nately." In the 18th century, Thomas
Watson described to the Royal Society his
postmortem findings of an asthma victim,
commenting on the overinflation of the
lungs even after their removal from the
thorax (1).
Despite this early and consistent recog-
nition of asthma as a serious, potentially
lethal disorder, the conception of asthma
underwent a change in the 19th century,
perhaps because physicians were so regu-
larly confronted with patients dying from
inexorably progressive tuberculosis.
Laennec, inventor of the stethoscope,
stated that asthma confers a prospect for
long life and freedom from other diseases.
Oliver Wendell Holmes described asthma
as "a slight ailment that prolongs
longevity." Even William Osler said, "The
asthmatic pants into old age" (1).
The general view held through the
middle ofthis century was that asthma is a
mild disease, possibly of psychosomatic
origin, requiring occasional or regular
bronchodilator therapy, with corticos-
teroids being reserved for severe acute
attacks or for the rare patient with chronic
severe asthma.
The observations responsible for chang-
ing this concept ofasthma, and ultimately
for the emergence of our current concept
of asthma's pathogenesis, derived from
studies of the epidemiology, physiology,
and pathology ofthe condition.
Increasing Morbidity and
Mortality of Asthma
That asthma is an important cause ofmor-
tality was dramatically reestablished by
sharp increases in asthma deaths, especially
in boys and young men, in the United
Kingdom in the mid 1960s and in New
Zealand in the late 1970s (2,3). These epi-
demics of asthma deaths caused other
countries to analyze their health statistics;
by the late 1980s, all developed western
countries with reliable statistics reported an
increase in asthma deaths (4,5). Recent
reports show these trends to have contin-
ued. The Centers for Disease Control
reported that asthma deaths increased 46%
from 1980 to 1989 (6). This increase was
shared by all races and age groups, but was
disproportionately greater in blacks and in
children. Geographic analysis showed dis-
proportionate increases in asthma deaths in
children in Chicago and New York City,
emphasizing the greater risk ofdeath from
asthma for the urban poor (7).
The increase in mortality may reflect a
true increase in the prevalence ofasthma. A
careful review ofthe diagnoses made at all
physician contacts in Olmsted County in
Minnesota, a county whose demographics
resemble those of the United States,
showed a 55% increase in the incidence of
asthma from 1964 to 1983 (8).
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The general-but not unanimous-
view among epidemiologists is that the
increase in deaths, hospitalizations, and
physician visits for asthma reflect a true
increase in the prevalence of the disease.
The reasons for this are unclear, but most
speculation centers on the changes in build-
ing insulation driven by the rising cost of
energy, a reduction in the turnover of
indoor air, and increased exposure to
indoor pollutants, especially environmental
cigarette smoke and the potent allergens of
cat dander, cockroaches, and house dust
mites. Well-designed epidemiologic studies
in England and Sweden show that the risk
ofdeveloping asthma is related to the level
ofhouse dust mites in household air (9,10).
As if the cost in human suffering was
not enough, the economic costs ofasthma
are great. Using data from the National
Center for Health Statistics and conserva-
tive estimates ofcost, an economic evalua-
tion of asthma placed the total cost in
1985 as $4.5 billion: $2.4 billion in direct
costs for inpatient, emergency, and outpa-
tient care, physicians' services and medica-
tions; and $2.1 billion in indirect costs for
loss ofwork and premature death (11).
Adjusted for inflation, this is $6.2 billion
in 1992 dollars. Asthma thus accounts for
about 1% ofall U.S. health care costs.
Bronchial Hyperreactivity
The other great changes in our conception
of asthma derived from studies of airway
responsiveness. It has been known for
more than 50 years that asthmatics
respond to inhalation ofvery low doses of
histamine or methacholine aerosol with
intense bronchoconstriction (12). This is a
persistent abnormality, easily demonstra-
ble even in asthmatics who are free of
symptoms and who have normal pul-
monary function at the time of testing.
The demonstration of the ubiquity of
bronchial hyperresponsiveness among
asthmatics (13) caused the concept of
asthma as an episodic disease to give way
to the concept of asthma as a chronic
abnormality in airway responsiveness that
causes intermittent symptoms.
Bronchial hyperresponsiveness has
come to be regarded as fundamental to
asthma's pathogenesis, not only because it
is ubiquitous in patients with the disease
but also because its degree correlates with
asthma's clinical severity. Bronchial
responsiveness has been found to increase
before the disease appears and to regress
only after the disease has entered clinical
remission.
Bronchial Hyperresponsive-
ness and Airway Mucosal
Inflammation
Bronchial responsiveness was thought to be
a fixed, possibly genetically determined
function until it was found that increases
in responsiveness could be induced in
healthy people by viral respiratory infec-
tions or by brief exposure to ozone
(14,15). Because both are inflammatory
stimuli, these findings prompted specula-
tion that bronchial responsiveness was
somehow linked to airway mucosal
inflammation (16). This idea has spawned
many studies, but the study that had per-
haps the greatest ultimate impact on theo-
ries ofasthma's pathogenesis was the report
that bronchial responsiveness increases for
as long as 7 to 12 weeks following a single
challenge with allergen in asthmatic sub-
jects, particularly in those who develop a
late asthmatic response 4 to 8 hr after the
antigen challenge (17).
To determine whether the increase in
responsiveness caused by antigen challenge
is associated with airway mucosal
inflammation, investigators have examined
bronchial lavage obtained at the time ofthe
late response (18,19). The fluid recovered
contains increased numbers ofeosinophils
and polymorphonuclear leukocytes
(PMN), just as are found in biopsies of
skin taken at the time ofthe late cutaneous
response to antigen injection (20).
The next step was logical. If the acute
increase in responsiveness caused by anti-
gen challenge is associated with an influx of
inflammatory cells into the airways, is the
hyperresponsiveness ofordinary asthma in
the baseline state also associated with the
presence of inflammatory cells in the
mucosa?
The best answer to this question has
been provided by studies ofairway mucosal
biopsies obtained by bronchoscopy of
healthy and asthmatic subjects (21,22).
Theses have been quite consistent in show-
ing disruption or desquammation of the
epithelium, subepithelial deposition ofcol-
lagen (causing the spurious appearance of
thickening of the basement membrane),
edema and eosinophilic and lymphocytic
infiltration of the lamina propria, and
hypertrophy or hyperplasia ofsubmucosal
glands and airway smooth muscle. The
findings in biopsies of people with mild
asthma differ in degree from those found
in patients dying of status asthmaticus, and
the demonstration that eosinophilic
inflammation is found even in mild asthma
has focused attention on the eosinophil as
playing a pivotal role in the pathogenesis of
asthma (23).
Role ofthe Eosinophil
A detailed morphologic study of biopsies
from 8 healthy and 34 asthmatic subjects
provided corroborating evidence of the
eosinophil's importance (23). This study
found a significant but unimpressive differ-
ence in the number of intra- and sub-
epithelial eosinophils in the mucosal
biopsies from the asthmatic subjects. The
difference became more impressive when
special stains were used for two ofthe gran-
ule proteins released by eosinophils that
have been activated eosinophil cationic
protein and eosinophil-derived neurotoxin.
These proteins were found outside the
eosinophils in the biopsies from the asth-
matic subjects, suggesting cell activation
and mediator release.
Further supporting the case for the
importance ofthe eosinophil are the results
of in vitro and animal studies that have
shown that eosinophil cationic protein
could cause all of the changes responsible
for airflow obstruction: increased contrac-
tile responsiveness ofairway smooth mus-
cle, increased vascular permeability, and
mucus secretion (24).
Role ofthe Lymphocyte
The other cell that attracted attention is
the lymphocyte, especially because the
irregular, ovoid shape oflymphocytes in
the biopsies from asthmatics suggested that
the cells might be activated.
Again, the most enlightening findings
came from studies ofairway mucosal biop-
sies. One such study used immunohisto-
chemical methods to compare the number
of cells expressing interleukin-2 (IL-2)
receptors, (taken to represent activated
lymphocytes) in biopsies ofproximal air-
ways from asthmatic subjects, from
nonasthmatic atopic subjects, and from
healthy subjects (25). At both levels ofthe
airways, the number ofIL-2-positive cells
was significantly greater in the asthmatic
subjects than in the other groups ofsub-
jects. The number of IL-2-positive cells
correlated with the number ofeosinophils
found in the same tissue.
The mechanism underlying this corre-
lation was suggested by another airway
biopsy study that examined tissues by in
situ hybridization for expression ofmRNA
for IL-5, a cytokine whose actions include
stimulation ofthe growth and activation of
eosinophils (26). Positive cells were found
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only in the biopsies from the asthmatic
subjects. These findings suggest that lym-
phocytes in asthmatic airways maysomehow
be activated to produce cytokines responsi-
ble for eosinophil growth, attraction,
and activation.
More recent studies have suggested pre-
dominance of a particular subtype oflym-
phocyte in asthmatic airways. These studies
have examined lymphocytes recovered
from bronchial lavage fluid obtained from
asthmatic and healthy subjects, analyzing
the pattern ofcytokine production by in
situ hybridization. The findings demon-
strate predominance of the TH2 subset in
asthmatic subjects (27). This subset ofT-
helper lymphocytes is characterized by its
production of a cluster of interleukins:
granulocyte macrophage colony stimulat-
ing factor (GM-CSF) and interleukins 3, 4,
5, and 10. Interleukin-4 is important in
directing plasma cells to make IgE and,
with IL-10, stimulates mast cell growth.
Interleukin-5 promotes in vitro survival
and activation of eosinophils, enhances
eosinophil adherence to endothelium, and
produces eosinophilia in vivo. GM-CSF
and IL-3 also contribute to eosinophil mat-
uration and differentiation.
Recently, Kay's group (28) has pro-
vided further evidence ofthe importance of
this family oflymphocytes. Using the same
methods, they showed an increase in the
number of cells expressing message for the
TH2 pattern ofinterleukins in bronchoalve-
olar lavage fluid obtained 24 hr after anti-
gen challenge. The number of CD4/
CD25+ cells in the fluid obtained corre-
lates both with the number ofcells express-
ing message for the TH2 interleukins and
with the number ofeosinophils found.
Synthesis into Conceptual
Model ofAsthma
These findings have led to the formulation
ofa conceptual model for the pathogenesis
of allergic asthma (29). The model pro-
poses that in a sensitized subject, the
sequence starts with exposure to an anti-
gen. The antigen binds to IgE on mast
cells, and perhaps on macrophages or other
cells, provoking secretion of the mediators
of immediate hypersensitivity like hista-
mine, prostaglandin D2, leukotrienes, and
tryptase. In animal models, these agents
cause many ofthe changes associated with
acute asthma: marked, reversible narrowing
of the airways from contraction of airway
smooth muscle, engorgement of the
mucosal vasculature, and mucosal edema.
To account for the late response, this
model proposes that the antigen is pre-
sented to a T-helper lymphocyte, provok-
ing it to produce interleukins that attract
eosinophils and polymorphonuclear leuko-
cytes and activate macrophages; these cells
in turn release products that stimulate
smooth-muscle contraction, edema, and
mucus hypersecretion. The model also pro-
poses that repeated activation oflympho-
cytes by repeated exposure to antigen
accounts for chronic stimulation of the
migration and activation ofeosinophils in
the airway mucosa, increasing airway
responsiveness and causing the repeated
bronchoconstriction typical ofasthma.
A point where this model may already
be out ofdate is in failing to recognize that
the mast cell is itself a potential source of
interleukins. Mast cells can synthesize
interleukins 3, 4, 5, 6, 8, tumor necrosis
factor, GM-CSF, and interferon-gamma
(30), and are potentially responsible for all
of the activities attributed to lymphocytes
in this model.
This model offers many potential sites
for therapeutic intervention ranging from
antigen avoidance to stabilizing the mast
cell, inhibiting the smooth muscle contrac-
tion, edema, and mucus secretion provoked
by mast cell derived mediators, destroying
lymphocytes or inhibiting their production
of interleukins, antagonizing the action of
the interleukins produced, preventing the
attachment or migration of inflammatory
cells, and, finally, to blocking the produc-
tion or action of the mediators released
from inflammatory cells. Ofthese possibili-
ties, the most elegant is to prevent the
entire cascade ofevents at the earliest possi-
ble point at the lymphocyte itself.
One ofthe agents most widely used for
treating asthma may in fact act through
inhibition oflymphocytes. Corticosteroids
have long been known to reduce lympho-
cyte numbers in the circulation and have
lately been shown to inhibit lymphocyte
production ofinterleukins (31); studies of
the effectiveness ofcorticosteroid therapy
in asthma might be interpreted as evidence
of the value oflymphocyte-directed ther-
apy. Many clinical trials have indeed
confirmed the efficacy of inhaled steroids
in reducing bronchial reactivity and in
improving symptoms ofasthma (32-34).
The National Institute of Health's
National Asthma Education Program rec-
ommends the early use ofinhaled corticos-
teroid for asthmatic patients with
symptoms not controlled by occasional use
inhaled beta agonists (35).
Limitations ofthe
Conceptual Model
Most ofthe studies that have examined the
validity of the conceptual model just
described have relied on the studies ofclin-
ical, physiologic, or morphologic changes
provoked by antigen challenge. Most
attacks of asthma presenting to hospital
emergency departments however cannot be
traced to exposure to allergens, but instead
appear to follow viral respiratory infections
(36). That this distinction may be impor-
tant was suggested by our own unexpected
findings in a simple descriptive study ofthe
constituents of the sputum spontaneously
produced by asthmatic patients presenting
for treatment to one of two large urban
hospital emergency departments (37).
Our analysis focused on the cellular
and chemical composition ofthe sputum.
Whereas the current model of asthma's
pathogenesis predicts that the predominant
cell would be the eosinophil, we found that
in the sputum produced by the 18 subjects
we studied, the predominant cell is the
PMN, not the eosinophil. In five of the
sputum samples, more than 90% of the
cells were PMNs, and in the samples from
all but three subjects, more than 50% of
the cells were PMNs. In only three subjects
did the sputum match the pattern pre-
dicted from the conceptual model. In these
samples, more than 75% of the cells were
eosinophils and fewer than 10% were
PMNs. None of these three patients
recalled a viral respiratory infection as pre-
ceding their attack; of the five with more
than 90% PMNs, four recalled such a
preceding illness.
The chemical profile was also different.
We found marked elevations of two inter-
leukins produced by airway epithelial cells:
interleukin-8, a potent chemoattractant for
PMNs, and in IL-6, an interleukin whose
actions are not well understood but that
include inhibition of endotoxin-induced
inflammation in rats. We could not detect
interleukin-4 or GM-CSF in these samples.
Also elevated markedly was the concen-
tration of neutrophil elastase. This serine
protease is released from PMNs and
potently stimulates submucosal gland
secretion (38). The high level of elastase
activity may thus account for the high con-
centrations of mucin, a product of goblet
and mucus cell secretion that we also
found in the samples we studied. Finally,
albumin, a marker of vascular extravasa-
tion, was also increased in the samples.
Volume 103, Supplement 6, September 1995 231BOUSHEYAND FAHY
These are just descriptive findings, but
they fit well with the mechanism proposed
for the pathogenesis ofmucus hypersecre-
tion in cystic fibrosis and bronchiectasis-
that mucus hypersecretion is the end result
of an inflammatory cascade that begins
with airway epithelial injury. This injury
stimulates IL-8 secretion and thus the
chemoattraction. Somehow, neutrophils
are activated to secrete elastase that in turn
stimulates mucin secretion from airway
goblet cells and submucosal glands (39).
At present, this line of reasoning is
speculative, but the point is not so much
whether it is correct but that it is only
possible because of findings made in
asthma as it occurs in the real world,
where attacks appear to be triggered most
often by viral infection. This is not to say
that the model derived from studies ofthe
response to antigen is irrelevant, it is
rather to say that it is incomplete.
Somehow, the mechanisms ofresponse to
antigen inhalation that are in place in the
asthmatic airway interact with the mecha-
nisms of response to viral infection or
other airway insult to provoke the events
ofacute severe attacks. How these systems
of response interact may be the next
major research issue for those interested in
asthma.
Results
Possible MFfects ofAirToxics in
AstmnaticPatients
Other papers presented at this symposium
directly consider the evidence that air toxics
have important adverse effects in asthmatic
patients. The conceptual model ofasthma
predicts several possible mechanisms of
interaction. One such mechanism has to do
with allergic sensitization ofthe airways
themselves. A genetically determined dispo-
sition is clearly important, and the concen-
tration ofcertain allergens in indoor air
appears to be an important co-factor (10).
The observation ofa strong influence of
maternal smoking as an additional factor
suggests that inhaled air pollutants and air
toxics may alter the integrity ofthe airway
epithelial barrier, increasing the ease ofsen-
sitization to inhaled allergen (40). This
possibility is supported bystudies ofmurine
and canine models in which concurrent
ozone exposure has been shown to facilitate
sensitization to an inhaled allergen (41,42).
Greater penetration of allergen may
account for the ozone's enhancement ofthe
response ofallergic subjects to intranasal
instillation ofallergen (43).
It should have been no surprise that
pollutants that cause bronchoconstriction
when inhaled in high concentration by
healthy subjects should provoke intense
bronchoconstriction even when inhaled in
low concentration by asthmatic subjects;
bronchial hyperresponsiveness to non-
specific inhaled stimuli has long been
known to be associated with asthma. This
has been confirmed repeatedly to be the
case for sulfur dioxide; asthmatics respond
to an order ofmagnitude lower concentra-
tions of SO2 than do nonasthmatics
(44,45). This may account for the associa-
tion of asthmatic symptoms and atmos-
pheric concentrations of sulfates in
epidemiologic studies (46). It would be
easier to make predictions about which
other inhaled materials should cause bron-
choconstriction ifwe had a better idea of
the mechanisms by which SO2 produces
this effect.
The study ofwhether and how inhaled
materials provoke cytokine release in the
airways, as ozone has been shown to do
from airway epithelial cells (47), has just
begun. That these important mediators of
cell to cell communication may have
important, even profound effects on air-
way function seems certain. As their cellu-
lar sources and effects are better
delineated, it will become easier to design
in vitro and animal studies ofthe effects of
air toxics that predict effects in subjects in
controlled exposure experiments and per-
haps even in population studies.
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